Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–72.

Article  PubMed  Google Scholar 

Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–16.

Article  PubMed  Google Scholar 

Tadayoni R. Choroidal neovascularization induces retinal edema and its treatment addresses this problem. J Ophthalmic Vis Res. 2014;9:405–6.

Article  PubMed  PubMed Central  Google Scholar 

Drolet DW, Green LS, Gold L, Janjic N. Fit for the eye: aptamers in ocular disorders. Nucleic Acid Ther. 2016;26:127–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Salehi-Had H, Dang W, et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci Trans Med. 2018;10:eaao4097.

Article  Google Scholar 

Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–9.

Article  PubMed  Google Scholar 

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. VIEW 1 and VIEW 2 study groups: Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.

Article  PubMed  Google Scholar 

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.

Article  Google Scholar 

Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC. Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2018;2:645–53.

Article  PubMed  Google Scholar 

Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, et al. Real-world outcomes in participants with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127–46.

Article  CAS  PubMed  Google Scholar 

Grunwald JE, Pistilli M, Daniel E, Ying GS, Pan W, Jaffe GJ, et al. Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials. Ophthalmology. 2017;124:97–104.

Article  PubMed  Google Scholar 

Krejci P, Prochazkova J, Bryja V, Kozubik A, Wilcox WR. Molecular pathology of the fibroblast growth factor family. Hum Mutat. 2011;30:1245–55.

Article  Google Scholar 

Marie PJ, Miraoui H, Severe N. FGF/FGFR signaling in bone formation: progress and perspectives. Growth Factors. 2012;30:117–23.

Article  CAS  PubMed  Google Scholar 

Schultz GS, Grant AB. Neovascular growth factors. Eye. 1991;1:70–80.

Google Scholar 

Vinding T. Occurrence of drusen, pigmentary changes and exudative changes in the macula with reference to age-related macular degeneration an epidemiological study of 1000 aged individuals. Acta Ophthalmol. 1990;68:410–4.

Article  CAS  Google Scholar 

Tomanek RJ, Sandra A, Zheng W, Brock T, Bjercke RJ, Holifield JS. Vascular endothelial growth factor and basic fibroblast growth factor differentially modulate early postnatal coronary angiogenesis. Circ Res. 2001;88:1135–41.

Article  CAS  PubMed  Google Scholar 

Belgore F, Lip GYH, Blann AD. Basic fibrobrast growth factor induces the secretion of vascular endothelial growth factor by human aortic smooth muscle cells but not by endothelial cells. Eur J Clin Invest. 2003;33:833–9.

Article  CAS  PubMed  Google Scholar 

Malabanan KP, Kanellakis P, Bobik A, Khachigian LM. Activation transcription factor-4 induced by fibroblast growth factor-2 regulates vascular endothelial growth factor-A transcription in vascular smooth muscle cells and mediates intimal thickening in rat arteries following balloon injury. Circ Res. 2008;103:378–87.

Article  CAS  PubMed  Google Scholar 

Cao R, Bråkenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med. 2003;9:604–13.

Article  CAS  PubMed  Google Scholar 

Birsner AE, Benny O, D’Amato RJ. The corneal micropocket assay: a model of angiogenesis in the mouse eye. J Vis Exp. 2014;90:e51375.

Google Scholar 

Matsuda Y, Nonaka Y, Futakawa S, Imai H, Akita K, Nishihata T, et al. Anti-angiogenic and anti-scarring dual action of an anti-fibroblast growth factor 2 aptamer in animal models of retinal disease. Mol Ther Nucl Acids. 2019;17:819–28.

Article  CAS  Google Scholar 

Jin L, Nonaka Y, Miyakawa S, Fujiwara M, Nakamura Y. Dual therapeutic action of a neutralizing anti-FGF2 aptamer in bone diseases and bone cancer pain. Mol Ther. 2016;24:1974–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oladipupo SS, Smith C, Santeford A, Park C, Sene A, Wiley LA, et al. Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc Natl Acad Sci USA. 2014;111:13379–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong Z, Santeford A, Ban N, Lee TJ, Smith C, Smith C, et al. FGF2-induced STAT3 activation regulates pathologic neovascularization. Exp Eye Res. 2019;187:107775.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, et al. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:656–66.

Article  PubMed  Google Scholar 

Jaffe GJ, Ciulla TA, Ciardella AP, Devin F, Dugel PU, Eandi CM, et al. Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration: a phase IIb, multicenter, randomized controlled trial. Ophthalmology. 2017;124:224–24.

Article  PubMed  Google Scholar 

Leung KFC, Downes SM, Chong V. Retrospective analysis of the effect of subretinal hyper-reflective material and other morphological features of neovascular age-related macular degeneration on visual acuity outcomes in eyes. Treated with intravitreal aflibercept over one year. Vision. 2018;2:5.

Article  PubMed  PubMed Central  Google Scholar 

Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193–201.

Article  PubMed  Google Scholar 

Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046–56.

Article  PubMed  Google Scholar 

Holekamp NM, Liu Y, Yeh WS, Chia Y, Kiss S, Almony A, et al. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am J Ophthalmol. 2014;157:825–33.

Article  PubMed  Google Scholar 

Rasmussen A, Bloch SB, Fuchs J, Hansen LH, Larsen M, LaCour M, et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120:2630–6.

Article  PubMed  Google Scholar